SSR 241586

Drug Profile

SSR 241586

Alternative Names: SSR241586

Latest Information Update: 17 Mar 2009

Price : $50

At a glance

  • Originator sanofi-aventis
  • Class Antidepressants; Antipsychotics; Anxiolytics; Irritable bowel syndrome therapies
  • Mechanism of Action Neurokinin 2 receptor antagonists; Neurokinin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Anxiety disorders; Irritable bowel syndrome; Major depressive disorder; Schizophrenia

Most Recent Events

  • 17 Sep 2007 Phase-I clinical trials in Anxiety disorders in France (unspecified route)
  • 17 Sep 2007 Phase-I clinical trials in Depression in France (unspecified route)
  • 17 Sep 2007 Phase-I clinical trials in Irritable bowel syndrome in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top